Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15055613 | 0.82 | ALDH1A1 (0.44) | ALDH1A1CNR2 | |
| SCHEMBL12395701 | 0.82 | ALDH1A1 (0.44) | ALDH1A1CNR2 | |
| SCHEMBL24532573 | 0.80 | MKNK1 (0.33) | MKNK1 | |
| SCHEMBL2911469 | 0.80 | MKNK1 (0.33) | MKNK1 | |
| Hydrochloric Acid SCHEMBL29091022 | 0.79 | MKNK1 (0.33) | MKNK1 | |
| Hydrochloric Acid SCHEMBL29091021 | 0.79 | MKNK1 (0.33) | MKNK1 | |
| SCHEMBL10330625 | 0.77 | MKNK1 (0.32) | ALDH1A1MKNK1 | |
| SCHEMBL15496990 | 0.77 | PLG (0.38) | CNR2 | |
| SCHEMBL14275282 | 0.76 | IRAK4 (0.33) | MKNK1 | |
| SCHEMBL29318379 | 0.75 | MKNK1 (0.33) | MKNK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120277434-A1 | METHODS FOR SYNTHESIZING QUINOLINONE COMPOUNDS | CAI SHAOPEI (US) | 2012-11-01 | — | — | US | disclosed |
| US-8299081-B2 | Methods for treating drug resistant cancer | NOVARTIS AG (CH) | 2012-10-30 | — | — | US | disclosed |
| US-8222413-B2 | Methods for synthesizing heterocyclic compounds | NOVARTIS AG (US) | 2012-07-17 | — | — | US | disclosed |
| US-20110046376-A1 | METHODS FOR SYNTHESIZING HETEROCYCLIC COMPOUNDS. | NOVARTIS AG (CH) | 2011-02-24 | — | — | US | disclosed |
| US-7825132-B2 | Inhibition of FGFR3 and treatment of multiple myeloma | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2010-11-02 | — | — | US | disclosed |
| US-20100184754-A1 | QUINOLINONE DERIVATIVES | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2010-07-22 | — | — | US | disclosed |
| US-20100184754-A1 | QUINOLINONE DERIVATIVES | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2010-07-22 | — | — | US | disclosed |
| US-20090281100-A1 | Benzimidazole quinolinones and uses thereof | BARSANTI PAUL A | 2009-11-12 | — | — | US | disclosed |
| US-7598268-B2 | Quinolinone derivatives | NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) | 2009-10-06 | — | — | US | disclosed |
| US-7598268-B2 | Quinolinone derivatives | NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) | 2009-10-06 | — | — | US | disclosed |
| US-20090215793-A1 | Methods for treating drug resistant cancer | NOVARTIS AG | 2009-08-27 | — | — | US | disclosed |
| US-7470709-B2 | Benzimidazole quinolinones and uses thereof | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2008-12-30 | — | — | US | disclosed |
| US-7368459-B2 | Heterocyclic compounds | CHIRON CORPORATION (US) | 2008-05-06 | — | — | US | disclosed |
| US-20080070906-A1 | QUINOLINONE DERIVATIVES | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2008-03-20 | — | — | US | disclosed |
| US-7335774-B2 | Quinolinone derivatives | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2008-02-26 | — | — | US | disclosed |
| US-7335774-B2 | Quinolinone derivatives | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2008-02-26 | — | — | US | disclosed |
| US-20070032528-A1 | Heterocyclic compounds | RENHOWE PAUL A | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070906-A1 | QUINOLINONE DERIVATIVES | SLCO1B1, SLCO1B3, SLCO1A2 | ALDH1A1 274/4885MKNK1 4561/4885CNR2 898/4885 |
| US-20070032528-A1 | Heterocyclic compounds | SLCO4C1, SLCO2B1, SLCO1B1 | ALDH1A1 1573/4885MKNK1 4227/4885CNR2 390/4885 |
| US-20120277434-A1 | METHODS FOR SYNTHESIZING QUINOLINONE COMPOUNDS | KCNJ2, KCNQ2, KCNJ11 | ALDH1A1 1983/4885MKNK1 648/4885CNR2 2451/4885 |
| US-20110046376-A1 | METHODS FOR SYNTHESIZING HETEROCYCLIC COMPOUNDS. | NISCH, DOHH, DNPH1 | ALDH1A1 1964/4885MKNK1 1307/4885CNR2 370/4885 |
| US-20090281100-A1 | Benzimidazole quinolinones and uses thereof | GAA, ALPI, IL4I1 | ALDH1A1 276/4885MKNK1 3605/4885CNR2 3723/4885 |
| US-20100184754-A1 | QUINOLINONE DERIVATIVES | SLCO1B1, SLCO1B3, SLCO1A2 | ALDH1A1 274/4885MKNK1 4561/4885CNR2 898/4885 |
| US-20090215793-A1 | Methods for treating drug resistant cancer | ABCC1, SLC11A2, SLC10A1 | ALDH1A1 1015/4885MKNK1 681/4885CNR2 4588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.